Asleep at the Switch
This article was originally published in RPM Report
Executive Summary
Drug reviews by FDA don't always go smoothly. In the case of Neurocrine Biosciences, things got really bumpy when implementation of an electronic NDA filing system came as the drug center was reorganizing its review divisions. Neurocrine says both factored into the delay of its investigational sleep agent indiplon.
You may also be interested in...
US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
‘The Gruber Moment’: How CBER Got The Answers It Wanted On COVID Vaccine Guidance
As US FDA recovers from aducanumab and looks towards an advisory committee on Pfizer’s COVID vaccine, it’s worth reflecting on how Office of Vaccine Research & Review Director Marion Gruber created positive turning points for the agency during a general discussion of vaccine approval standards at the VRBPAC.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: